Stay One Move Ahead
See Resistance
Before It Happens.
Cymoplive makes adaptive cancer behaviour visible early enough to act.
See Resistance
90%
of drug candidates fail in human trials.
Late-stage resistance and poor predictivity derail the majority of therapies.
3–5%
of cancer drugs entering trials ever reach approval.
The success rate in oncology remains critically low.
€50–60B
lost annually in failed oncology R&D.
Billions are spent advancing therapies that ultimately do not translate.
50–100M
animals used every year in research.
Yet existing models still fail to reliably predict human cancer behaviour.
Cancer Doesn’t Fail Drugs.
It Adapts to Them.
Most screening systems measure early response, not how cancer fights back. Adaptive escape often remains invisible until in vivo studies, or worse, clinical trials. High-stakes decisions are made on short-term data.
That gap costs time, capital and opportunity.
Cymoplive Reveals What Others Miss.
Cymoplive is a human-relevant platform that reveals how cancer truly behaves under tissue-like conditions, revealing whether tumours stop, adapt, or escape and how that behaviour unfolds over time.
Our Pipeline
Breakthrough Discoveries
01
MarGel™
Our proprietary organ-like hydrogel engineered to recreate human-relevant physiological conditions and preserve tumour heterogeneity as observed in human cancers.
02
OncoTrix™
OncoTrix™ is a first-in-class platform that uses structured conditions to reveal functional adaptive behaviours of cancer cells missed by existing systems.
03
CellTraceD™
Live behavioural scoring that converts adaptive behaviour into actionable measures of cancer aggressiveness, drug efficacy pharmacodynamics, resistance/relapse risk, and combination performance.
Why You Can Trust Cymoplive
We are Proven, Protected and Human-Relevant.
Cymoplive is a patented platform delivering time-resolved adaptive behaviour insights under controlled conditions.
Our core platform and analytics are protected by filed patents and validated in human carcinoma models, including pancreatic, triple-negative breast, and cervical cancers.
Proven
Protected
Human-Relevant
Funding & Core Partners
Act Before Resistance Becomes Expensive
Gain early insight into resistance risk and make smarter pipeline decisions, in collaboration with Cymoplive.